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Abstract 
 
Background: According to previous reports from many countries (e.g., the United States, Germany, the United Kingdom), 
the use of antipsychotic drugs has increased among young people. Antipsychotics have also increasingly been prescribed for 
non-psychotic disorders. 
Objective: The purpose of this study was to estimate the rate at which antipsychotics were prescribed for young people in 
the age groups of 10 to 14 years, 15 to 19 years, and 20 to 24 years in Finland in the years 2000, 2005, and 2010. 
Methods: This was a nationwide register study using data from the databases of Statistics Finland and the Finnish National 
Prescription Register. Statistics Finland’s databases provided background information, including the total number of young 
people and the Finnish National Prescription Register keeps record of all drug orders reimbursed by the Social Insurance 
Institution of Finland. 
Results: The prescription of antipsychotics grew 6.8-, 4.6-, and 2.6-fold over the study period for these three age groups, 
respectively. For the youngest age group, use was more common among males than females in all three periods studied. 
During the course of the study period, the use of antipsychotics became more common among females: in 2010, antipsychotics 
were more commonly used among females than males in both the 15- to 19-year-old age group and the 20- to 24-year-old age 
group. The younger the patient, the higher the probability that the indication for medication was a non-psychotic disorder. 
Conclusions: In Finland, the trends involved in the prescription of antipsychotic medications resemble those seen in many 
Western countries. Therefore, it is important that the safety and effectiveness of these pharmaceuticals be investigated among 
young people as well. 
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Introduction 
In many countries (e.g., the United States, Canada, 
the United Kingdom), since the introduction of the 
second-generation antipsychotics, antipsychotic 
medications have been increasingly prescribed for 
adults as well as children and adolescents (1-4). 
According to a previous study, there was a nine-fold 
increase in the prescription of antipsychotics for 
children from the years 1993 through 1998 to the 
years 2005 through 2009 in the United States (5). The 
current practice is to treat even behavioral problems 
with antipsychotics, and today the majority of 
antipsychotic medications prescribed for  
 
children and adolescents are for the treatment of 
disruptive behavior (6). Prepubertal children who 
receive antipsychotic medication are usually male and 
being treated for attention-deficit/hyperactivity 
disorder and conduct disorders (3,4). Among both 
youth and adults, the proportion of second-
generation antipsychotics prescribed for the 
treatment of schizophrenia has decreased, whereas 
the treatment of anxiety disorders with 
antipsychotics has roughly doubled (5). In a large 
convenience sample of adolescent psychiatric 
outpatients, 77% of those who were receiving 
antipsychotic medication did not have a diagnosis of 
a psychotic disorder (7). 
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In terms of effectiveness, the differences among 
various antipsychotics are relatively small, and they 
mostly concern adverse effects (8). Children and 
adolescents seem to have a higher risk than adults of 
experiencing adverse events, such as extrapyramidal 
symptoms, prolactin elevation, sedation, weight gain, 
and metabolic effects (9). The typical side effects of 
second-generation antipsychotics include weight 
gain, dyslipidemia, and hyperglycemia, all of which 
increase the risk for cardiovascular disease (10). 
There is increasing concern about the negative 
effects of antipsychotics; before treatment with any 
antipsychotic is begin, a careful risk–benefit 
assessment should be conducted (8). 
The purpose of this study was to assess trends in 
the prescription of antipsychotic medications for 
young people in Finland during the first decade of 
the twenty-first century, both overall and separately 
for the genders as well as separately for psychotic and 
non-psychotic disorders.  
 
Methods 
This was a national register study that made use of 
information extracted from the databases of two 
registers: Statistics Finland and the Finnish National 
Prescription Register. Statistics Finland’s databases 
served as the source of population statistics, which 
included the number of young people in the three age 
groups (i.e., 10 to 14 years, 15 to 19 years, and 20 to 
24 years) in the years 2000, 2005, and 2010. The age 
groups were chosen to align with the practices of the 
Finnish National Prescription Register, which keeps 
records of all drug orders reimbursed by the Social 
Insurance Institution of Finland. Every individual 
with at least one reimbursed prescription was 
considered to be a potential case for this study. 
“Higher special reimbursement for difficult 
psychosis and other difficult mental health 
problems” constituted a category of its own; in 
practice, this means that all young people who are 
entitled to “higher special reimbursement” have 
psychotic symptoms.  
The drugs in the register are coded using the 
Anatomical Therapeutic Chemical classification 
system; for the antipsychotics, the associated code is 
N05A (11). The data recorded in the register include 
patients’ ages and genders. 
In this study, the prevalence of the prescription of 
antipsychotics was calculated for the three different 
age groups, for both genders together, and for 
females and males separately and then compared for 
the years 2000, 2005, and 2010. The actual prevalence 
was calculated as the proportion of the individuals 
with reimbursed prescriptions for antipsychotics in 
relation to the total number of age- and gender-
matched individuals at the given time. The use of 
antipsychotics for psychosis was also analyzed 
separately for the same age groups and the same 
years. The differences between the genders were 
estimated by comparing the prevalence rates for 
antipsychotic use in each study year with the use of 
chi-squared tests. Chi-squared tests were also used to 
assess the rate of antipsychotic medication 
prescribed specifically for psychotic disorders as well 
as the change in antipsychotic usage throughout the 
study period. The change in the rate of antipsychotic 
usage was assessed by comparing the usage rates 
from 2010 with those from 2000. The statistical 
analyses were carried out with the use of SAS 9.2 
software. 
 
Results 
The prevalence of the prescription of antipsychotic 
medications throughout the study period is presented 
in Table 1. The rate of antipsychotic usage increased 
many times over from 2000 to 2010, and the 
differences were statistically significant (p < .001). As 
shown in the table, depending on the age group, the 
use of antipsychotics grew three- to five-fold in 
females and two- to seven-fold in males.  
The prevalence of the prescription of 
antipsychotics specifically for psychotic disorders 
was also assessed separately, and the results are 
presented in Table 2. These analyses also 
demonstrated a multi-fold increase from 2000 to 
2010 in the prescription of antipsychotics, and the 
changes in the rates were statistically significant (p 
< .001) for all age groups. The proportion of cases 
that involved a psychotic disorder being the 
indication for the prescribed antipsychotic 
medication increased with age (Figure 1).  
 
Discussion 
According to this study, the prescription of 
antipsychotics for young people increased multiple 
times in Finland from 2000 to 2010, and this was also 
the case in other countries, including the United 
States and Canada (2-5). There was an increase in the 
prescription of antipsychotics for psychotic disorders 
as well as for non-psychotic indications. In Canada, 
the use of antipsychotic medications for the 
treatment of schizophrenia in patients who were less 
than 18 years old remained stable between the years 
of 1999 and 2008 (2). 
In the youngest age group (10 to 14 years old), the 
use of antipsychotic medication was more common 
among males than among females throughout the 
study period. This is in accordance with previous 
reports from the United States, Canada, and 
Germany, which suggests that, in the youngest age 
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TABLE 1. The prevalence of the prescription of antipsychotic drugs to Finnish children and adolescents in 2000, 2005, and 2010. The results are presented for three 
age groups (10 to 14 years old, 15 to 19 years old, and 20 to 24 years old) as well as separately by gender 
 
  2000 2005 2010 Growth* 
  N Prevalence N Prevalence N Prevalence  p† 
10 to 14 years 
old 
Entire age class  318,634 0.10%  
(n = 323) 
328,539 0.25%  
(n = 818)  
296,709 0.68%  
(n = 2024) 
6.8 <.001 
Females 155,687 0.07%  
(n = 106) 
161,212 0.11%  
(n = 179) 
145,131 0.34%  
(n = 487) 
4.9 <.001 
Males 162,947 0.13%  
(n = 217) 
167,327 0.38%  
(n = 639) 
151,578 1.01%  
(n = 1537) 
7.8 <.001 
p‡ <.001 <.001 <.001   
15 to 19 years 
old 
Entire age class 331,778 0.33%  
(n = 1099) 
320,942 0.64%  
(n = 2042) 
332,084 1.46%  
(n = 4835) 
4.6 <.001 
Females 162,161  0.33%  
(n = 532) 
156,824 0.83%  
(n = 1143) 
162,860 1.67%  
(n = 2724) 
5.1 <.001 
Males 169,617 0.33%  
(n = 567) 
164,118 0.55%  
(n = 899) 
169,224 1.25%  
(n = 2111) 
3.8 <.001 
p‡ .76 <.001 <.001   
20 to 24 years 
old 
 
Entire age class 327,230 0.79%  
(n = 2597) 
333,936 1.16%  
(n = 3863) 
327,780 2.02%  
(n = 6616) 
2.6 <.001 
Females 160,146 0.66%  
(n = 1060) 
163,226 1.11%  
(n = 1809) 
159,963 2.23%  
(n = 3569) 
3.4 <.001 
Males 167,084 0.92%  
(n = 1537) 
170,710 1.20%  
(n = 2054) 
167,817 1.82%  
(n = 3047) 
2.0 <.001 
p‡ <.001 .011 <.001   
*Increase in the prescription of antipsychotics from 2000 to 2010 (fold) 
†Chi-squared test, comparison between 2000 and 2010 
‡Chi-squared test, comparison between genders 
 
 
 
TABLE 2. The prevalence of the prescription of antipsychotic drugs for the treatment of psychotic disorders among Finnish children and 
adolescents in 2000, 2005 and 2010. The results are presented for three age groups: 10 to 14 years old, 15 to 19 years old, and 20 to 24 years old 
 
 2000 2005 2010 Growth* 
 N Prevalence N Prevalence N Prevalence  p† 
10 to 24 years old, in total  977,642 0.21% 
(n = 2056) 
983,417 0.39% 
(n = 3865) 
956,573 0.47% 
(n = 4482) 
2.2 <.001 
10 to 14 years old 318,634 0.015% 
(n = 48) 
328,539 0.044% 
(n = 143) 
296,709 0.071% 
(n = 212) 
3.5 <.001 
15 to 19 years old 331,778  0.14% 
(n = 456) 
320,942 0.29% 
(n = 923) 
332,084 0.35% 
(n = 1177) 
2.5 <.001 
20 to 24 years old 327,230 0.47% 
(n = 1552) 
333,936 0.84% 
(n = 2799) 
327,780 0.94% 
(n = 3093) 
2.0 <.001 
*Increase in the prescription of antipsychotics from 2000 to 2010 (fold) 
†Chi-squared test, comparison between 2000 and 2010 
 
 
 
FIGURE 1. The percentage of antipsychotic drugs prescribed for non-psychotic and psychotic conditions  
among Finnish children and adolescents between the ages of 10 and 24 years in 2000, 2005, and 2010 
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group, users of antipsychotic medications are mostly 
boys (3,4,12). In 2005, the prescription of 
antipsychotics was more common among 15- to 19-
year-old females than among males in the same age 
group. In 2010, the use of antipsychotics was more 
common among females than among males in those 
15 to 19 years old and 20 to 24 years old. The trends 
seen in Finnish practice may grow closer to those 
seen in the United States, where antipsychotic use 
was significantly greater for female adults than male 
adults (≥21 years old) between 1993 and 2009 (5). 
In Finland, there are few official indications for 
antipsychotic use in children: risperidone is used for 
conduct disorders associated with aggressiveness 
from the age of 5 years; ziprasidone is used for 
bipolar disorder from the age of 10 years; 
aripiprazole is used for bipolar disorder from the age 
of 13 years and for schizophrenia from the age of 15 
years; and clozapine is used for patients who are 
more than 15 years old for treatment refractory 
schizophrenia. However, the off-label use of 
antipsychotics is very common, and children and 
adolescents often receive drugs that are not licensed 
for use by minors (13). This practice is an overall 
problem in the treatment of children, with 50% to 
75% of the prescription of drugs to children 
estimated to involve off-label use (17). 
Antipsychotics are prescribed for children and 
adolescents for many indications without being 
backed up by scientific data regarding their 
effectiveness and safety. It is likely that 
antipsychotics are often used for the treatment of 
attention-deficit/hyperactivity disorder and conduct 
disorders (15,16). There are also reports about the 
widened use of atypical antipsychotics for anxiety 
and depressive disorders (5). 
The increase in the prescription of antipsychotics 
has taken place despite the accumulating evidence of 
their serious side effects (9,10). Children and 
adolescents are at increased risk for antipsychotic-
related side effects as compared with adults (8). 
Metabolic and endocrine abnormalities cause the 
most concern. In addition, there are insufficient data 
available regarding the long-term effects of these 
pharmaceuticals (16). 
For child and adolescent patients, treatment is 
administered during a time of rapid brain 
development. Thus, it is essential to evaluate the 
possible effects—whether favorable or 
detrimental—of antipsychotic medications on 
cognition and other aspects of brain maturation at 
various ages and with various durations of exposure 
(16).  
 
 
Clinical Significance 
The prevalence of the prescription of antipsychotics 
has increased with the introduction of the second-
generation antipsychotics in Finland as well as in 
several other Western countries. It is important that 
the safety and effectiveness of these pharmaceuticals 
be carefully studied for use among children and 
adolescents and for the treatment of various 
disorders. 
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